SCHEDULE 13G/A: Vanguard Group Discloses 4.45% Passive Stake in Ginkgo Bioworks Holdings Inc.
Beneficial Ownership Disclosure
The Vanguard Group has filed an amended Schedule 13G, reporting a 4.45% beneficial ownership stake in Ginkgo Bioworks Holdings Inc. as of December 31, 2024.
Summary
- The Vanguard Group, an investment adviser, reported beneficial ownership of 2,013,548 shares of Ginkgo Bioworks Holdings Inc. Common Stock.
- This aggregate amount represents 4.45% of the class of securities.
- Vanguard holds 0 shares with sole voting power and 5,567 shares with shared voting power.
- Vanguard holds 1,981,080 shares with sole dispositive power and 32,468 shares with shared dispositive power.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Vanguard's clients, including registered investment companies and other managed accounts, have the right to receive dividends or proceeds from the sale of these securities, with no single client holding more than 5%.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing passive beneficial ownership. It contains factual information without any positive or negative operational or financial news, thus maintaining a neutral sentiment.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a large institutional investor, The Vanguard Group, indicating its passive ownership stake in Ginkgo Bioworks Holdings Inc. It reflects a standard investment position within the biotechnology and synthetic biology sector, where institutional holdings are common. It does not provide specific insights into Ginkgo Bioworks' operational performance or strategic direction, but rather Vanguard's portfolio allocation.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming a passive investment approach by The Vanguard Group.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement (reporting period end date). |
| 01/30/2025 | Date the Schedule 13G Amendment No. 4 was signed by The Vanguard Group. |
Keywords
Ginkgo Bioworks Holdings Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.